

Verici Dx plc
("Verici Dx" or the "Company")

Clarava™ poster to be presented at ASN Kidney Week

International clinical validation study data to be presented at the largest global gathering of kidney health professionals

Verici Dx plc (AIM: VRCL), a developer of advanced clinical diagnostics for organ transplant announces that it will present a poster on the successful international clinical validation study for Clarava™, the Company's pre-transplant blood-based prognostic test for the risk of early acute kidney transplant rejection, at the American Society of Nephrology's annual conference, *ASN Kidney Week*, being held from 2-5 November 2023 in Philadelphia, PA.

The poster, titled "*Multi-Center International Study to Validate a Pre-Transplant Blood-Based Next-Generation Sequencing (NGS) Signature Predicting Risk of Acute Rejection After Kidney Transplant*" will be presented from 10am-12pm on 2 November, in the Exhibit Hall at location TH-PO115.

The poster will describe the design and positive results of Clarava's™ successful validation study, as previously announced, and is expected to help establish the product within the international nephrology community ahead of commercial launch.

Clarava™ is the only pre-transplant test of its kind currently available that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including increasing or decreasing adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardised and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As previously reported, the Clarava™ personalised risk assessment is especially important for the expanding Deceased Donor transplant population.

Sara Barrington, CEO of Verici Dx, said: "ASN Kidney Week is an important platform for Verici Dx to raise awareness of its products including Clarava™, being the largest international gathering attended by kidney health professionals and featuring the latest advances in treatment, research and cutting edge technology in the field of nephrology."

Enquiries:

Verici Dx
Sara Barrington, CEO
Julian Baines, Chairman

www.vericidx.com
Via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)
Aubrey Powell / Sam Butcher / Jalini Kalaravy

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus / Sam Allen

Tel: 020 7933 8780 or vericidx@walbrookpr.com
Mob: 07980 541 893 / 07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFSFESFEDSESF